Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
As its share price faces pressure, the latest remarks by Intel CEO Pat Gelsinger may help ease market concerns over Intel's role in the Terafab collaboration.
On October 7, according to Bloomberg, Pat Gelsinger stated in an interview in Tokyo that Intel will continue to participate in Terafab. Intel signed on as a development partner for the project in April this year, and his latest comments indicate that, despite recent changes in the collaboration, Intel has not withdrawn from the project.
The new uncertainty arises from TSMC. Earlier this week, Elon Musk revealed he is in talks with TSMC about potential collaboration on Terafab. Previously, Musk had excluded the possibility of TSMC operating Terafab; now with cooperation discussions resuming, it has raised market concerns over whether TSMC's possible involvement will impact Intel's role in the project. Following the news, Intel's share price once fell by 3.9%.
Terafab is Elon Musk’s initiative to enter the cutting-edge chip manufacturing sector and is also an important cooperation project for Intel to participate in the latest wave of semiconductor capacity expansion. Currently, as governments and enterprises accelerate AI deployment, demand for chips and related components continues to rise. The global semiconductor industry is ramping up capacity, with several sectors of the supply chain facing supply pressures.
Bloomberg previously reported that Musk has asked suppliers to push forward the Terafab plan at "light speed." Right now, factories for items such as ball bearings, chip manufacturing equipment, industrial chemicals, and rails are all running at full capacity, prompting companies to speed up the construction of new production lines.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.
Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.
Crypto prices
More
